[Prospective randomized multicenter phase III study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate].
Weissbach
L
L
Urologische Abteilung Krankenhaus am Urban, Berlin, Bundesrepublik Deutschland.
D015251:Epirubicin / Q000008:administration & dosage*; D004961:Estramustine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage*; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004961:Estramustine; D015251:Epirubicin; D016685:Mitomycin
Prospektive randomisierte multizentrische Phase III-Studie zur Behandlung des hormonrefraktären Prostatakarzinoms: Mitomycin C vs. 4-Epirubicin vs. Estramustinphosphat.